Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased as a result of growth in sales of key strategic products and expanded XTANDI sales. Profit increased due to foreign exchange effects, SMT-led cost optimization, higher clinical development costs for key strategic products and the pipeline, and a decrease in other expenses, among other factors.
No applicable matters ("There are no applicable matters")
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥640,914 million (YoY +26.7%) |
| Operating profit | ¥184,506 million (YoY +94.9%) |
| Ordinary income | ¥186,514 million (YoY +106.3%) |
| Profit attributable to owners of the parent | ¥141,828 million (YoY +107.3%) |
| Net income per share | 79.15 |
| Equity ratio | End of the current fiscal period 52.6% / End of previous period 51.3% |
| Total assets | ¥3,692,526 million |
| Net assets | ¥1,944,449 million |
| Cash flows from operating activities | ¥86,476 million |
| Cash flows from investing activities | ¥-69,243 million |
| Cash flows from financing activities | ¥-52,948 million |
| Cash and cash equivalents at end of period | ¥244,698 million |
| Full-year earnings forecast | Net Sales ¥2,220,000 million (YoY +3.8%) / Operating profit ¥395,000 million (YoY +3.2%) / Ordinary income ¥385,000 million (YoY +2.2%) / Net income ¥300,000 million (YoY +2.9%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥78.00 → ¥80.00（2.6%） |
| Regional sales | United States 2,888 Hundreds of millions of yen (YoY +28.5%) / Japan 796 Hundreds of millions of yen (YoY +15.5%) / Established Markets 1,522 Hundreds of millions of yen (YoY +18.2%) / China 321 Hundreds of millions of yen (YoY +8.9%) / International Markets 854 Hundreds of millions of yen (YoY +60.5%) |
| Impairment loss | ¥49 million |
| Disclosure regarding the going concern assumption | No applicable matters ("There are no applicable matters") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New Not disclosed / Excluded Not disclosed / Company name Not disclosed / Material changes No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Securities analysts, institutional investors and media organizations |
| Issued Shares at Period-End | 1,809,663,075 Shares |
| Treasury Shares at Period-End | 16,649,328 Shares |
| Factors Behind Changes in Business Performance | Revenue increased as a result of growth in sales of key strategic products and expanded XTANDI sales. Profit increased due to foreign exchange effects, SMT-led cost optimization, higher clinical development costs for key strategic products and the pipeline, and a decrease in other expenses, among other factors. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales of key strategic products, including PADCEV, IZERVAY, VYLOY, VEOZAH and XOSPATA, increased, while XTANDI sales also expanded. On the profit front, although foreign exchange effects and higher clinical development costs for key strategic products and the pipeline had an impact, SMT-led cost optimization was implemented and other expenses decreased from the same period of the previous fiscal year.